Immunitybio Stock Market Outlook
| IBRX Stock | USD 8.51 0.75 9.66% |
This sentiment measure is descriptive rather than personalized advice and should be used with other evidence before acting on it. Around 55% of recent sentiment around Immunitybio has been mildly constructive over the recent sample. Taken on its own, that leaves the current sentiment reading for Immunitybio close to neutral right now.
Investor Comfort Level
PanicConfidence
55 · Impartial
Maximum Pain Price Across 2026-07-17 Option Contracts
Immunitybio max pain for the 2026-07-17 contracts is 7.50. Open interest around that strike level helps frame how options positioning may interact with price. Immunitybio put open interest of 11.9 K contracts at the 9.00 strike versus call open interest of 13.3 K contracts at the 9.00 strike reflects how the options market is pricing directional risk into this cycle.
Elasticity to Hype and News Sentiment
Immunitybio news coverage registers mixed at 43%, a data point that gauges whether public narrative is leading or lagging the business reality. Comparing perception data with actual financial results can separate headline-driven pressure from genuine fundamental change.
Given a 90-day horizon, with an above-average risk tolerance, the model output for Immunitybio is 'Strong Sell'. Our automated recommendation for Immunitybio is built from quantitative evidence and fundamental indicators. The analysis combines quantitative signals with investor-specific risk parameters. The recommendation evaluates return potential against downside risk within defined investment parameters. Complementing automated signals with independent research strengthens the broad analytical foundation.
Immunitybio |
Run Immunitybio Outlook Model
Our Immunitybio outlook engine provides a data-driven supplement to the analyst consensus on Immunitybio. Macroaxis has no vested interest in Immunitybio or any other instrument analyzed here. Multiple quantitative inputs drive the Immunitybio's signal across different market conditions. Combining algorithmic signals with independent analysis supports more informed decisions.
How This Model Works
The recommendation output for Immunitybio is a model-based view that converts the selected horizon and risk profile into a standardized reading of the current evidence.
- Inputs - valuation signals, price behavior, volatility, liquidity, sentiment, and analyst coverage when available
- Current setup - Three Months with a risk setting described as I am an educated risk taker
- Limits - the model does not account for taxes, outside holdings, concentration constraints, or investor-specific mandates
Use the output as structured decision support and pair it with your own research, portfolio context, and any professional advice you rely on.
Time Horizon
Risk Tolerance
Strong Sell
Market Performance | Contained | Details | |
Volatility | Elevated | Details | |
Current Valuation | Below Model Estimate | Details | |
Odds Of Distress | Very High | Details | |
Economic Sensitivity | Moves totally opposite to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Healthy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Immunitybio's current outlook reflects a cautious setup, where weak recent performance and soft fundamental readings cloud near-term visibility. The model's 'Strong Sell' signal reflects persistent headwinds that outweigh the offsetting factors in the model. For the selected horizon, Immunitybio yields Mean Deviation of 5.84, Semi Deviation of 6.61, and Standard Deviation of 8.74, which weigh on the current risk-reward outlook.The quantitative analytical reading for Immunitybio blends historical performance patterns with current market conditions and the analyst and expert consensus to frame the risk-reward profile. For additional context on this mid-cap stock in the Health Care sector, review the full set of Immunitybio reported fundamentals, including the relationship between the cash flow from operations ttm and trailing beta. Immunitybio reports a price to sales ttm of 63.22 X. Its market performance and financial distress probability provide additional context.
Recent Events and Market Context
The events below reflect recent headlines associated with Immunitybio. Not all items directly affect the outlook — they are included to show the broader information environment that can shape sentiment and trading behavior.
Returns Distribution Density
Plotting Immunitybio's daily returns in a distribution reveals the day-to-day behavior of Immunitybio. It shows how returns are grouped around the average and how often large swings occur. Value At Risk and Upside Potential quantify both the risk and the reward. Value At Risk shows the worst-case boundary and Upside Potential shows the best-case boundary.
| Mean Return | 0.92 | Value At Risk | -10 | Potential Upside | 14.55 | Standard Deviation | 8.74 |
Return Density |
| Distribution |
Risk management for Immunitybio depends on quantifying the frequency and magnitude of extreme moves. The distribution chart below makes that clear for Immunitybio. Portfolio managers weigh the trade-offs across risk-return profiles. Return distribution analysis highlights the frequency and magnitude of extreme price moves in Immunitybio.
Top Institutional Investors
Immunitybio's institutional and insider mix shapes how the stock trades around earnings. Annual revenue is about 113.29 million. The business currently sits in the Health Care sector and the Pharmaceuticals, Biotechnology & Life Sciences industry. With moderate institutional presence, retail activity has more room to move the price day to day.
| Shares | Charles Schwab Investment Management Inc | 2025-12-31 | 2.5 M | Barclays Plc | 2025-12-31 | 2.4 M | Bank Of America Corp | 2025-12-31 | 2.4 M | Tang Capital Management Llc | 2025-12-31 | 2.3 M | Northern Trust Corp | 2025-12-31 | 2.2 M | Voleon Capital Management Lp | 2025-12-31 | 1.5 M | Squarepoint Ops Llc | 2025-12-31 | 1.5 M | Skandinaviska Enskilda Banken Ab | 2025-12-31 | 1.3 M | Renaissance Technologies Corp | 2025-12-31 | 1.2 M | Vanguard Group Inc | 2025-12-31 | 32.8 M | Blackrock Inc | 2025-12-31 | 25.6 M |
Cash Flow Accounts
| 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Dividends Paid | 4.4M | 334.4M | 616K | 708.4K | 673.0K |
Key Drivers of Volatility and Market Exposure
Market risk ties Immunitybio to macro cycles, whereas company or sector-specific developments represent independent drivers. Volatility metrics help measure this balance. For Immunitybio, recent data highlights a Downside Deviation of 7.60, a Mean Deviation of 5.84, and an Option Implied Volatility of 1.42.
α | Alpha over Dow Jones | 0.88 | |
β | Beta against Dow Jones | -0.9795 | |
σ | Overall volatility | 8.65 | |
Ir | Information ratio | 0.11 |
Fundamentals Vs Peers
Immunitybio is measured here against stocks with similar revenue scale, margin profile, and capital structure. The comparison below reveals whether Immunitybio generates superior or inferior returns relative to similar stocks. Divergence between Immunitybio's valuation multiples and its peer group flags either mispricing or a structural difference in quality. Direct comparison with similar stocks converts Immunitybio's standalone financial data into an actionable relative signal.
| Better Than Average | Worse Than Average | Compare Immunitybio to competition |
Note: Acquisition by Selecky Christobel of 50000 shares of Immunitybio at 2.98 subject to Rule 16 b-3 [view details]
Market Momentum
Beta of -0.9795 dampens broad market moves. Immunitybio market-strength view helps distinguish trend continuation from fading momentum. Immunitybio timing discipline improves when momentum indicators are cross-checked with volume and earnings revision context.
Recommendation Framework, Assumptions & Editorial Oversight
The model output for Immunitybio reflects the current horizon and risk settings, refreshes as underlying data changes, and is intended to organize evidence rather than replace investor judgment. Current model inputs for Immunitybio include market cap of 8.91 billion. External analyst coverage is currently summarized as Strong Buy across 5 analysts, but it is treated here as a secondary reference input rather than a stand-alone recommendation. Published target-price assumptions may also be reviewed when available, but they can change quickly as analyst models are revised. 
Immunitybio metrics draw on periodic company reporting and market reference feeds, standardized for cross-period comparison. The model combines valuation, price behavior, volatility, and sentiment into a standardized quantitative view.
Editorial Review & Methodology Oversight
Role: Member of Macroaxis Editorial Board
Finance background: Gabriel is a young entrepreneur and writes predominantly on the business, technology, and finance sector. He likes to analyze different equity instruments across a wide range of industries focusing primarily on consumer products and evolving technologies.
Oversight scope: Reviews recommendation-framework framing, source assumptions, and disclosure language.